drugset / Trial / NCT02581891

Managing Neovascular (Known as "Wet") Age-related Macular Degeneration Over 2 Years Using Different Treatment Schedules of 2 mg Intravitreal Aflibercept Injected in the Eye

NCT02581891

Phase 4 Completed 287 enrolled Bayer Regeneron Pharmaceuticals · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

This study aims to evaluate the optimal use, efficacy, and safety of a Treat-and-Extend regimen with aflibercept in subjects with nAMD.

Timeline

Start
2015-11-19
Primary completion
2019-04-26
Completion
2019-04-26

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Aflibercept Protein / enzyme biologic 2 mg Intravitreal

Indications